Literature DB >> 22308561

A controlled trial of a cognitive skills program for personality-disordered offenders.

Susan Young1, Gareth Hopkin, Derek Perkins, Catherine Farr, Amie Doidge, Gisli Gudjonsson.   

Abstract

OBJECTIVE: There is a need to find effective treatments for individuals with antisocial and borderline personality disorder who are known to be difficult to engage and treat. Many of these individuals share considerable overlap with symptoms of ADHD, hence this study aimed to evaluate the Reasoning and Rehabilitation ADHD program (R&R2 ADHD) among patients with severe personality disorder.
METHOD: A total of 31 males detained in a "dangerous and severe personality disorder" unit completed questionnaires at baseline and post treatment to assess social problem solving, violent attitudes, anger, ADHD symptoms, emotional control, and social functioning. A total of 16 patients participated in the group condition, and their scores were compared with 15 waiting-list controls who received treatment as usual.
RESULTS: In all, 76% of group participants completed the program. In contrast to controls, they showed significant improvements in scores with mainly medium effect sizes.
CONCLUSION: R&R2 ADHD was effective in a small sample of severely personality-disordered offenders.

Entities:  

Keywords:  ADHD; personality disorders; social cognition; treatment

Mesh:

Year:  2012        PMID: 22308561     DOI: 10.1177/1087054711430333

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  8 in total

1.  A multi-site controlled trial of a cognitive skills program for mentally disordered offenders.

Authors:  Angharad Rees-Jones; Gisli Gudjonsson; Susan Young
Journal:  BMC Psychiatry       Date:  2012-05-18       Impact factor: 3.630

2.  Psychological interventions for antisocial personality disorder.

Authors:  Simon Gibbon; Najat R Khalifa; Natalie H-Y Cheung; Birgit A Völlm; Lucy McCarthy
Journal:  Cochrane Database Syst Rev       Date:  2020-09-03

3.  Cognitive-behavioural therapy in medication-treated adults with attention-deficit/hyperactivity disorder and co-morbid psychopathology: a randomized controlled trial using multi-level analysis.

Authors:  S Young; M Khondoker; B Emilsson; J F Sigurdsson; F Philipp-Wiegmann; G Baldursson; H Olafsdottir; G Gudjonsson
Journal:  Psychol Med       Date:  2015-05-29       Impact factor: 7.723

Review 4.  Effect of treatment modality on long-term outcomes in attention-deficit/hyperactivity disorder: a systematic review.

Authors:  L Eugene Arnold; Paul Hodgkins; Hervé Caci; Jennifer Kahle; Susan Young
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

5.  Beyond the Gates: Identifying and Managing Offenders with Attention Deficit Hyperactivity Disorder in Community Probation Services.

Authors:  Susan Young; Gisli H Gudjonsson; Emily J Goodwin; Amit Jotangia; Romana Farooq; David Haddrick; Marios Adamou
Journal:  AIMS Public Health       Date:  2014-03-17

6.  Prevalence of Attention Deficit Hyperactivity Disorder in Detention Settings: A Systematic Review and Meta-Analysis.

Authors:  Stéphanie Baggio; Ana Fructuoso; Marta Guimaraes; Eveline Fois; Diane Golay; Patrick Heller; Nader Perroud; Candy Aubry; Susan Young; Didier Delessert; Laurent Gétaz; Nguyen T Tran; Hans Wolff
Journal:  Front Psychiatry       Date:  2018-08-02       Impact factor: 4.157

7.  A non-randomised controlled trial of the R&R2MHP cognitive skills program in high risk male offenders with severe mental illness.

Authors:  Vivienne C-Y Yip; Gisli H Gudjonsson; Derek Perkins; Amie Doidge; Gareth Hopkin; Susan Young
Journal:  BMC Psychiatry       Date:  2013-10-18       Impact factor: 3.630

8.  A national epidemiological study investigating risk factors for police interrogation and false confession among juveniles and young persons.

Authors:  Gisli H Gudjonsson; Jon Fridrik Sigurdsson; Inga Dora Sigfusdottir; Bryndis Bjork Asgeirsdottir; Rafael A González; Susan Young
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-11-04       Impact factor: 4.328

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.